✦ LIBER ✦

Intensive alternating drug pairs for treatment of high-risk childhood acute lymphoblastic leukemia. A pediatric oncology group pilot study

✍ Scribed by Stephen J. Lauer; Bruce M. Camitta; Brigid G. Leventhal; Donald H. Mahoney Jr.; Jonathan J. Shuster; Stuart Adair; James T. Casper; Curt I. Civin; Michael Graham; Geri Kiefer; Jeanette Pullen; C. Philip Steuber; Barton Kamen

Publisher: John Wiley and Sons
Year: 1993
Tongue: English
Weight: 682 KB
Volume: 71
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19930501)71:9<2854::aid-cncr2820710929>3.0.co;2-j

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A comparison of two regimens for high-ri

A comparison of two regimens for high-risk acute lymphocytic leukemia in childhood. A pediatric oncology group study

✍ Jan Van Eys; Daisilee Berry; William Crist; Ed Doering; Donald Fernbach; Jeanett 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 624 KB

Four hundred thirty patients with high-risk acute lymphoid leukemia were entered on the acute leukemia in childhood protocol (AlinC 12) of the Pediatric Division of the Southwest Oncology Group (now the Pediatric Oncology Group) between 1976 and 1979. This study was a prospective randomized comparis

Treatment intensity and outcome for chil

Treatment intensity and outcome for children with acute lymphocytic leukemia of standard risk. A pediatric oncology group study

✍ Jan van Eys; Daisilee Berry; William Crist; Ed Doering; Donald Fernbach; Jeanett 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 485 KB 👁 2 views

Four hundred thirty-four children, with good-risk acute lymphocytic leukemia (ALL), were assigned randomly to receive intensive or less intensive maintenance therapy with 6-mercaptopurine and methotrexate, plus vincristine and prednisone pulses in such a way that patients on treatment 1 had their le

Alternating drug pairs with or without p

Alternating drug pairs with or without periodic reinduction in children with acute lymphoblastic leukemia in second bone marrow remission : A Pediatric Oncology Group study

✍ George R. Buchanan; Gaston K. Rivera; Brad H. Pollock; James M. Boyett; Allen R. 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB 👁 2 views

## Background: Children with acute lymphoblastic leukemia (all) who experience hematologic recurrence while receiving chemotherapy or within 6 months after its cessation have a low cure rate. in this study (pediatric oncology group protocol 8303) two methods were examined for improving the outcome

Repetitive low dose oral methotrexate an

Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B—lineage acute lymphoblastic leukemia. A pediatric oncology group pilot study

✍ Donald H. Mahoney Jr.; Bruce M. Camitta; Brigid G. Leventhal; Jonathan J. Shuste 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 822 KB

Teniposide (VM-26) and continuous infusi

Teniposide (VM-26) and continuous infusion cytosine arabinoside for initial induction failure in childhood acute lymphoblastic leukemia. A pediatric oncology group pilot study

✍ Judith Ochs; Gaston K. Rivera; Brad H. Pollock; George Buchanan; William Crist; 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 595 KB

A pilot study of intermediate-dose metho

A pilot study of intermediate-dose methotrexate and cytosine arabinoside, “Spread-out” or “Up-front,” in continuation therapy for childhood non-T, non-B acute lymphoblastic leukemia a pediatric oncology group study

✍ Robert A. Krance; Edward M. Newman; Donald Pinkel; Yaddanapudi Ravindranath; Mic 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 723 KB

One hundred six children with newly diagnosed non-T-, non-B-cell acute lymphoblastic leukemia (ALL) were treated in a Pediatric Oncology Group (POG) pilot study in which six courses of intermediate-dose methotrexate (MTX) and cytosine arabinoside (Ara-C) (1 g/m2 each) were added to a "backbone" of s